Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,765
Views
8
CrossRef citations to date
0
Altmetric
Editorial

NK cells beat T cells at early breast cancer control

Aitziber Buquea Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
,
Norma Bloya Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
,
Giulia Petronia Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
,
Guido Kroemerb Equipe Labellisée Par la Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France;c Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;d Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;e Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China;f Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon &
Lorenzo Galluzzia Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA;g Sandra and Edward Meyer Cancer Center, New York, NY, USA;h Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA;i Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA;j Université de Paris, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2257-8500
ORCID Icon
Article: 1806010 | Received 20 Jul 2020, Accepted 31 Jul 2020, Published online: 23 Aug 2020

References

  • Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–3. doi:10.1038/nature21349.
  • Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:eaat7807. doi:10.1126/scitranslmed.aat7807.
  • Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. doi:10.1038/35074122.
  • Buque A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A, et al. Immunosurveillance of hormone receptor-positive breast cancer - Prophylactic and therapeutic effects of nicotinamide. Nat Commun. 2020;in press. doi:10.1038/s41467-020-17644-0.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi:10.3322/caac.21590.
  • Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514–524. doi:10.1056/NEJMoa1911149.
  • Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Tourneau CL, van Brummelen EMJ, Varga A, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res. 2018;24:2804–2811. doi:10.1158/1078-0432.CCR-17-3452.
  • Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21:1128–1138. doi:10.1038/nm.3944.
  • Buque A, Galluzzi L. Modeling Tumor Immunology and Immunotherapy in Mice. Trend Cancer. 2018;4:599–601. doi:10.1016/j.trecan.2018.07.003.
  • Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30:147–160. doi:10.1016/j.ccell.2016.05.016.
  • Galluzzi L, Yamazaki T, Kroemer G. Linking cellular stress responses to systemic homeostasis. Nat Rev Mol Cell Biol. 2018;19:731–745. doi:10.1038/s41580-018-0068-0.
  • Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121:3609–3622. doi:10.1172/JCI45816.
  • Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mab is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731–43 e13. doi:10.1016/j.cell.2018.10.014.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.